Premature ejaculation is one of the most common sexual dysfunction diseases in male clinical practice, with an incidence of 20%-30%, which can seriously affect the quality of sexual life of patients. The cause of premature ejaculation is not clear, and there are no special treatment drugs. However, a large amount of clinical data shows that antidepressants are satisfactory in the treatment of premature ejaculation and have received important attention in the treatment of premature ejaculation. It has been found that 5-hydroxytryptamine (5-HT) and its receptors play an important role in the physiological ejaculation process, and reduced 5-HT release/reuptake of increased 5-HT1A/5-HT2C receptor dysfunction may be associated with premature ejaculation. The mechanism of action of antidepressants is to inhibit 5-HT reuptake, increase the concentration of 5-HT in the synaptic gap, and activate postsynaptic membrane-associated 5-HT receptors, thereby increasing the ejaculatory threshold and exerting a delayed ejaculatory effect. The main antidepressants used to treat premature ejaculation are dapoxetine, paroxetine, sertraline, etc., of which sertraline hydrochloride is the most commonly used. 1, sertraline hydrochloride Sertraline hydrochloride tablets (Zoloft) can inhibit the reabsorption of compound amines in the blood by neurons in the central nervous system. One of its side effects is to raise the threshold of male and female sexual arousal and orgasm, inhibit male and female sexual desire and delay the onset of male and female orgasm, so theoretically its side effects can be used to achieve the purpose of treating premature ejaculation. It has been reported that patients taking sertraline hydrochloride about 3 hours before sexual intercourse can significantly delay the time to ejaculation. The adverse effects of sertraline hydrochloride are mild and transient and may be related to mild anticholinergic effects. The most common adverse effects include loss of appetite, nausea, diarrhea, and insomnia, but the incidence is low. Precautions: (1) Use with caution in patients with closed-angle glaucoma, epilepsy, and severe heart disease; (2) Use with caution or reduce the dosage in patients with hepatic or renal insufficiency; (3) Discontinue immediately if there is a tendency to manic episodes; (4) Do not drive vehicles, operate machinery, or work at height during the use of the drug. Dapoxetine is the only short-acting SSRI used for the treatment of premature ejaculation. It has a rapid onset of action (peak time of about 1.3 h) and a short half-life (24-h clearance rate of about 95%), and studies have found that it is suitable for both primary and secondary premature ejaculation. It has the following advantages: on-demand and rapid onset of action. Improved ejaculatory control, prolonged intravaginal ejaculation time (2.5-3 times longer) and significantly higher satisfaction with intercourse. Compared with traditional SSRI, dapoxetine offers great convenience to patients and as the number of dapoxetine doses increases, when the cumulative number of doses is about 30 capsules, the duration of sexual intercourse can be maintained at the level of the drug taken even when the drug is discontinued, minimizing the adverse effects caused by long-term use. The most common adverse reactions to dapoxetine include nausea, dizziness, drowsiness, diarrhea, headache, and vomiting, which are generally mild and their severity is positively correlated with the dose taken. In addition, even within the safe dose range, dapoxetine may cause serious adverse reactions in the cardiovascular system such as sinus bradycardia, sinus arrest, ventricular tachycardia, and syncope, but further confirmation from clinical studies is needed. Precautions: (1) Do not take dapoxetine with concomitant psychoactive controlled substances; (2) Avoid alcohol; (3) Do not drive vehicles, operate machinery or work at height while taking dapoxetine; (4) Prohibited in patients with moderate and severe liver injury.